Enrollment underway in phase 2 trial of nasal spray for neurotrophic keratopathy
Click Here to Manage Email Alerts
Oyster Point Pharma has enrolled the first patient in a phase 2 clinical trial investigating the safety and efficacy of OC-01 nasal spray in patients with neurotrophic keratopathy, according to a press release.
The randomized, multicenter, double-masked, placebo-controlled OLYMPIA trial of OC-01 (varenicline) nasal spray is expected to enroll about 100 patients with Mackie’s classification stage 1 neurotrophic keratopathy across 18 U.S. sites. The primary endpoint is the percentage of patients who achieve complete resolution of corneal fluorescein staining at day 56.
“This is an exciting milestone as we continue to develop this potentially new treatment option for patients with stage 1 neurotrophic keratopathy,” Jeffrey Nau, PhD, MMS, president and CEO of Oyster Point Pharma, said in the release.
Read more about
Click Here to Manage Email Alerts